Desing of cancer vaccines based on MUC1-Like Glycopeptides Containing Non-Natural Amino Acids

  1. Ó. Suárez 1
  2. A. Avenoza, 1
  3. J.M. Peregrina 1
  4. M. Zurbano 1
  5. F. Corzana 1
  6. J. H. Busto 1
  7. F. García-Martín 1
  1. 1 Universidad de La Rioja
    info

    Universidad de La Rioja

    Logroño, España

    ROR https://ror.org/0553yr311

Actas:
XXXVIII Reunión Bienal de la Real Sociedad Española de Química - RSEQ 2022 (Abstracts book)

Editorial: Real Sociedad Española de Química

ISBN: 978-84-09-42159-6

Ano de publicación: 2022

Páxinas: 1135

Congreso: XXXVIII Reunión Bienal de la Real Sociedad Española de Química (RSEQ). Granada 27-30 de junio de 2022

Tipo: Cartel do Congreso

beta Ver similares en nube de resultados
GOOGLE SCHOLAR lock_openAcceso aberto editor
Repositorio institucional: lock_openAcceso aberto Editor

Resumo

The Tn antigen (GalNAc-α-1-O-Thr) is a well-known tumor-associated carbohydrate determinant. The use of glycopeptides with this structure (e.g., mucin 1, MUC1) has become a promising field of research due to their potential use as cancer vaccines.[1] However, current vaccine candidates generally have weak in vivo immune responses due to their low stability and immunogenicity.[2]To address these drawbacks, we will modify several residues in the peptide sequence of MUC1 by unnatural amino acids, such as β-amino acids,[3] or surrogates of arginine residue.In this study, the synthetic routes and challenges encountered in obtaining the various homologues will be described. The affinity of a library of glycopeptides containing β-amino acids for the anti-MUC1 SM3 antibody will be presented and preliminary results will be discussed along with future prospects.

Referencias bibliográficas

  • [1] I. A. Bermejo, C. D. Navo, et al. Chem. Sci. 2020, 11, 3996–4006.
  • [2] I. Compañón, A. Guerreiro et al. J. Am. Chem. Soc. 2019, 141, 4063–4072.
  • [3] R. Gibadullin, C. J. Randall, J. Sidney, A. Sette, S. H. Gellman. J. Am. Chem. Soc. 2021, 143, 6470–6481.